Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Real-World Characteristics, Step-up Dosing Patterns, and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab at Texas Oncology Community-Based Treatment Centers

Yair Levy, Nina Kim, Siraje Mahmud, Bingcao Wu, Laura Ensley, Dee Lin, Monica Lisi, Felice Yang, Lorraine Brisbin, Jessica Fowler, Laura Hester, Agne Paner-Straseviciute, Sian Walker, Christina Hearty, R. Steven Paulson

Blood (2024) 144 (Supplement 1): 7851.

https://doi.org/10.1182/blood-2024-210497

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7843.

https://doi.org/10.1182/blood-2024-208708

Published: 2024

Journal Articles

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Blood (2024) 144 (Supplement 1): 7854.

https://doi.org/10.1182/blood-2024-210841

Published: 2024

Journal Articles

Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings

Aimaz Afrough, Adeel M Khan, Eric Chinaeke, Nina Kim, Jinghua He, Elissa E. Min, Bingcao Wu, Dee Lin, Agne Paner-Straseviciute, Laura Hester, Jessica Fowler, Sian Walker, Christina Hearty, Larry D Anderson, Jr.

Blood (2024) 144 (Supplement 1): 933.

https://doi.org/10.1182/blood-2024-209008

Published: 2024

Journal Articles

Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting

Timothy C. Beer, Gloria HJ Graf, Dee Lin, Mariana Fernandez, Margaret Doyle, Laura L. Hester, Bingcao Wu, Stephen Huo

Blood (2024) 144 (Supplement 1): 2398.

https://doi.org/10.1182/blood-2024-203379

Published: 2024

Journal Articles

Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Rahul Banerjee, Nina Kim, Monal Kohli, Emeka Umeh, Dee Lin, Gideon Aweh, Jessica Fowler, Emily Achter, Laura Hester, Sian Walker, Christina Hearty, Bingcao Wu

Blood (2024) 144 (Supplement 1): 3792.7.

https://doi.org/10.1182/blood-2024-210750

Published: 2024

Journal Articles

Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab

Brittany Grossi, Nina Kim, Monal Kohli, Bingcao Wu, Emeka Umeh, Dee Lin, Gideon Aweh, Emily Achter, Laura Hester, Sian Walker, Christina Hearty, Peter M. Voorhees

Blood (2024) 144 (Supplement 1): 3783.

https://doi.org/10.1182/blood-2024-208509

Published: 2024

Journal Articles

A Mixed Methods Study to Describe the Relationship between Burden of Illness, Social Needs, and Identity Experiences Among Patients with Multiple Myeloma

Natalia Neparidze, Amandeep Godara, Dee Lin, Hoa H. Le, Karen Fixler, Lisa Shea, Stephanie Everson, Christine Brittle, Kimberly Brunisholz

Blood (2023) 142 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2023-178893

Published: 2023

Journal Articles

Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals - an Updated Analysis Using Premier Healthcare Database

Carlyn Rose Tan, Nina Kim, Eric Chinaeke, Laura Hester, Jessica Fowler, Dina Gifkins, Dee Lin, Sian Walker, Alex Z. Fu, Bingcao Wu

Blood (2023) 142 (Supplement 1): 3792.

https://doi.org/10.1182/blood-2023-178896

Published: 2023

Journal Articles

Evolving Real-World Characteristics and Step-up Dosing Among Early Initiators of Teclistamab for Multiple Myeloma - a National All-Payer Claims Database Study

Rahul Banerjee, Nina Kim, Monal Kohli, Laura Hester, Emily Achter, Jessica Fowler, Emeka Umeh, Dee Lin, Gideon Aweh, Dina Gifkins, Sian Walker, Bingcao Wu

Blood (2023) 142 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2023-178908

Published: 2023

Journal Articles

Panel Interview of Oncology Practices with Emergent Experience of Teclistamab in the Real World: The Tec-Pioneer Study

Ben A Derman, Meaghan Roach, Dee Lin, Bingcao Wu, Richard Murphy, Nina Kim, Margaret Doyle, Nadya Prood, Jessica Fowler, Alexander Marshall, Amal Jamaleddine, Agne Paner-Straseviciute

Blood (2023) 142 (Supplement 1): 7249.

https://doi.org/10.1182/blood-2023-187479

Published: 2023

Journal Articles

Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration

Tyler B. Sandahl, Scott A. Soefje, Ediz S. Calay, Yi Lin, Rafael Fonseca, Sikander Ailawadhi, Ricardo Parrondo, Dee Lin, Bingcao Wu, Eli Silvert, Nina Kim, Corinne Carpenter, Tyler E. Wagner, Jessica Fowler, Laura Hester, Alexander Marshall, Patrick Stoy, Dina Gifkins, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2023-174270

Published: 2023

Journal Articles

A US National View of Prevalent and Newly Diagnosed Multiple Myeloma in 2021: A Retrospective Analysis of National All-Payer Claims Database

Dee Lin, Yihang Liu, Nina Kim, Savanna Ledford, Aerin Sun, Kimberly Brunisholz, Rohan Medhekar, Lisa Abramovitz, Keshia Maughn, Victor Johnson, Michael Schultz, Bingcao Wu

Blood (2022) 140 (Supplement 1): 932–933.

https://doi.org/10.1182/blood-2022-167474

Published: 2022

Journal Articles

Patients' and Caregivers' Perspectives from Social Media Towards Disease Burden and Innovative Treatment Options in Multiple Myeloma

Dee Lin, Jordan Richardson, Nina Kim, Savanna Ledford, Josh Feldman, Paul Boyce, Bingcao Wu

Blood (2022) 140 (Supplement 1): 5244–5245.

https://doi.org/10.1182/blood-2022-167813

Published: 2022

Journal Articles

Burden of Hospitalization before and after a Disease Progression Following Triple-Class Exposure in Patients with Relapsed and Refractory Multiple Myeloma

Jennifer S Harper, Alex Z. Fu, Dee Lin, Bingcao Wu, Nina Kim, Savanna Ledford, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 5214–5215.

https://doi.org/10.1182/blood-2022-167617

Published: 2022

NARROW

Real-World Characteristics, Step-up Dosing Patterns, and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab at Texas Oncology Community-Based Treatment Centers

Real-World Patient Characteristics and Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Real-World Patient Characteristics and Outcomes in Patients with High-Risk Cytogenetic Relapsed or Refractory Multiple Myeloma Receiving Teclistamab across Community Oncology Practices in the US

Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings

Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting

Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab

A Mixed Methods Study to Describe the Relationship between Burden of Illness, Social Needs, and Identity Experiences Among Patients with Multiple Myeloma

Real-World Patient Profile and Step-up Dosing Process of Early Initiators of Teclistamab for Multiple Myeloma in US Hospitals - an Updated Analysis Using Premier Healthcare Database

Evolving Real-World Characteristics and Step-up Dosing Among Early Initiators of Teclistamab for Multiple Myeloma - a National All-Payer Claims Database Study

Panel Interview of Oncology Practices with Emergent Experience of Teclistamab in the Real World: The Tec-Pioneer Study

Real-World Treatment Outcomes of Teclistamab Under an Outpatient Model for Step-up Dosing Administration

A US National View of Prevalent and Newly Diagnosed Multiple Myeloma in 2021: A Retrospective Analysis of National All-Payer Claims Database

Patients' and Caregivers' Perspectives from Social Media Towards Disease Burden and Innovative Treatment Options in Multiple Myeloma

Burden of Hospitalization before and after a Disease Progression Following Triple-Class Exposure in Patients with Relapsed and Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only